
FTH Stock Forecast & Price Target
FTH Analyst Ratings
Bulls say
Faeth Therapeutics is in a strong position with their promising new cancer treatment, PIKTOR, which has shown early potential in reducing side effects for endometrial and breast cancer patients. The company's financial position allows for continued development until 2028, and their previous data gives them a head start in identifying the ideal dose and regimen for the drug. While facing competition, Faeth's unique dosing schedule and potential for long-term use make them a potential leader in the field, aided by positive regulatory feedback and historical data.
Bears say
Faeth Therapeutics is a clinical-stage biotechnology company with a promising drug candidate, PIKTOR, in development for endometrial and breast cancer. Despite having raised $200 million for clinical development and having a strong partner for commercialization, there is a risk of failure in the drug's development, which could negatively impact the company's financials. The expertise of the Chief Commercial Officer offers some confidence in the drug's potential, but the lengthy timeline for a top-line readout in 2026 may discourage investor sentiment.
This aggregate rating is based on analysts' research of Sensei Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FTH Analyst Forecast & Price Prediction
Start investing in FTH
Order type
Buy in
Order amount
Est. shares
0 shares